In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.

Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.

Medical experts provide insights on factors impacting SMA treatment strategies.

Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. This is the first part of a three-part video series.

A lack of guidelines impair the management of Demodex blepharitis.

Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Douglas K. Devries, OD, discusses how Demodex blepharitis affects patients’ quality of life and associated financial burden.

Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.